1. Home
  2. ITRG vs RLMD Comparison

ITRG vs RLMD Comparison

Compare ITRG & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Integra Resources Corp.

ITRG

Integra Resources Corp.

HOLD

Current Price

$2.37

Market Cap

529.9M

ML Signal

HOLD

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

HOLD

Current Price

$6.57

Market Cap

661.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ITRG
RLMD
Founded
1997
2004
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
529.9M
661.9M
IPO Year
2017
2012

Fundamental Metrics

Financial Performance
Metric
ITRG
RLMD
Price
$2.37
$6.57
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$5.13
$12.40
AVG Volume (30 Days)
3.6M
1.3M
Earning Date
05-11-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
45.28
EPS
N/A
N/A
Revenue
N/A
$13,070.00
Revenue This Year
$67.34
N/A
Revenue Next Year
$25.89
N/A
P/E Ratio
$45.07
N/A
Revenue Growth
N/A
154.83
52 Week Low
$1.43
$0.53
52 Week High
$4.87
$8.00

Technical Indicators

Market Signals
Indicator
ITRG
RLMD
Relative Strength Index (RSI) 40.54 47.02
Support Level $2.32 $6.17
Resistance Level $3.29 $7.46
Average True Range (ATR) 0.15 0.43
MACD 0.01 0.05
Stochastic Oscillator 16.30 61.15

Price Performance

Historical Comparison
ITRG
RLMD

About ITRG Integra Resources Corp.

Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Share on Social Networks: